| Literature DB >> 26030312 |
Akihiro Sugawara1, Nobuo Maita2, Hiroaki Gouda3, Tsuyoshi Yamamoto1, Tomoyasu Hirose1, Saori Kimura1, Yoshifumi Saito1, Hayato Nakano1, Takako Kasai1, Hirofumi Nakano1, Kazuro Shiomi1, Shuichi Hirono3, Takeshi Watanabe4, Hisaaki Taniguchi2, Satoshi Omura1, Toshiaki Sunazuka1.
Abstract
Argifin, a 17-membered pentapeptide, inhibits chitinase. As argifin has properties that render it unsuitable as a drug development candidate, we devised a mechanism to create the structural component of argifin that bestows the chitinase inhibition and introduce it into a 14-membered macrolide scaffold. Here we describe (1) the designed macrolide, which exhibits ∼200-fold more potent chitinase inhibition than argifin, (2) the binding modes of the macrolide with Serratia marcescens chitinase B, and (3) the computed analysis explaining the reason for derivatives displaying increased inhibition compared to argifin, the macrolide aglycone displaying inhibition in a nanomolar range. This promises a class of chitinase inhibitors with novel skeletons, providing innovative insight for drug design and the use of macrolides as adaptable, flexible templates for use in drug discovery research and development.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26030312 DOI: 10.1021/acs.jmedchem.5b00175
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446